Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Monday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of NYSE BTX opened at $1.79 on Monday. The stock has a market cap of $105.30 million, a price-to-earnings ratio of -0.79 and a beta of 4.61. The business has a 50 day simple moving average of $1.79 and a 200 day simple moving average of $1.99. Brooklyn ImmunoTherapeutics has a 52 week low of $0.17 and a 52 week high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.